Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors
Summary
This phase II trial is studying how well combination chemotherapy, radiation therapy, and/or surgery work in treating patients with high-risk kidney tumors. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving combination chemotherapy together with radiation therapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.
Timeline
- Start
- 2006-06
- Primary completion
- 2015-12
- Completion
- —
Outcome
Mixed primary results
registry NUMBER UH-1: 76.1 (62.5 to 89.6) Percentage of 4-year OS NCT00335556 ↗
registry NUMBER Window/UH-1: 25.0 (0 to 67.4) Percentage of 4-year OS NCT00335556 ↗
registry analysis (other test); UH-1 vs Window/UH-1 vs UH-2; p = .0199; Log Rank Test Statistic 5.4190; Log Rank NCT00335556 ↗
registry analysis (other test); UH-1; p = .3478; Log Rank Test Statistic .8814; Log Rank NCT00335556 ↗
registry analysis (other test); Regimen DD-4A; p = .0570; Log Rank Test Statistic 3.6216; Log Rank NCT00335556 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | — | Intravenous |
| Subject | Cyclophosphamide | Other / unclassified | — | Intravenous |
| Subject | Dactinomycin | Unknown | — | Intravenous |
| Subject | Doxorubicin | Other / unclassified | — | Intravenous |
| Subject | Etoposide | Small molecule | — | Intravenous |
| Subject | Irinotecan | Small molecule | — | Intravenous |
| Subject | Vincristine | Small molecule | — | Intravenous |